AU2020233876B2 - Growth differentiation factor 15 combination therapy - Google Patents

Growth differentiation factor 15 combination therapy

Info

Publication number
AU2020233876B2
AU2020233876B2 AU2020233876A AU2020233876A AU2020233876B2 AU 2020233876 B2 AU2020233876 B2 AU 2020233876B2 AU 2020233876 A AU2020233876 A AU 2020233876A AU 2020233876 A AU2020233876 A AU 2020233876A AU 2020233876 B2 AU2020233876 B2 AU 2020233876B2
Authority
AU
Australia
Prior art keywords
gdf15
seq
nos
gipr
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020233876A
Other languages
English (en)
Other versions
AU2020233876A1 (en
Inventor
Murielle Marie VENIANT ELLISON
Yumei Xiong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2020233876A1 publication Critical patent/AU2020233876A1/en
Application granted granted Critical
Publication of AU2020233876B2 publication Critical patent/AU2020233876B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020233876A 2019-03-08 2020-03-06 Growth differentiation factor 15 combination therapy Active AU2020233876B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815866P 2019-03-08 2019-03-08
US62/815,866 2019-03-08
PCT/US2020/021314 WO2020185533A1 (en) 2019-03-08 2020-03-06 Growth differentiation factor 15 combination therapy

Publications (2)

Publication Number Publication Date
AU2020233876A1 AU2020233876A1 (en) 2021-09-23
AU2020233876B2 true AU2020233876B2 (en) 2026-02-12

Family

ID=70166143

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020233876A Active AU2020233876B2 (en) 2019-03-08 2020-03-06 Growth differentiation factor 15 combination therapy

Country Status (7)

Country Link
US (1) US20220152154A1 (enExample)
EP (1) EP3934679A1 (enExample)
JP (2) JP7536030B2 (enExample)
AU (1) AU2020233876B2 (enExample)
CA (1) CA3131912A1 (enExample)
MX (1) MX2021010737A (enExample)
WO (1) WO2020185533A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN117106085A (zh) * 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
US12054527B2 (en) 2018-04-09 2024-08-06 Amgen Inc. Growth differentiation factor 15 fusion proteins
ES3061099T3 (en) 2019-10-04 2026-03-31 Amgen Inc Use of gdf15 for treating cardiometabolic syndrome and other conditions
EP4244246A1 (en) * 2020-11-10 2023-09-20 Amgen Inc. Novel linkers of multispecific antigen binding domains
EP4351627A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
EP4619423A1 (en) * 2022-11-18 2025-09-24 Yuhan Corporation Dual function proteins and uses thereof
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160120999A1 (en) * 2014-10-31 2016-05-05 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2019048660A1 (en) * 2017-09-10 2019-03-14 Novo Nordisk A/S MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740096D1 (de) 1996-08-08 2011-02-17 Amylin Pharmaceuticals Inc Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
CA2309356C (en) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999040788A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
RU2242244C2 (ru) 1999-01-14 2004-12-20 Амилин Фармасьютикалз, Инк. Новые композиции агонистов эксендина и способы их введения
JP2002538084A (ja) 1999-01-14 2002-11-12 アミリン・ファーマシューティカルズ，インコーポレイテッド グルカゴンを抑制する方法
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
WO2001051078A1 (en) 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
JP6254146B2 (ja) * 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
CA2899170C (en) * 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
CN117106085A (zh) 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
EP4480537A3 (en) 2017-01-17 2025-03-12 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
US12054527B2 (en) * 2018-04-09 2024-08-06 Amgen Inc. Growth differentiation factor 15 fusion proteins
MY205905A (en) * 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160120999A1 (en) * 2014-10-31 2016-05-05 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2019048660A1 (en) * 2017-09-10 2019-03-14 Novo Nordisk A/S MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HENRIETTE FRIKKE-SCHMIDT, KARIN HULTMAN, JOSEPH W. GALASKE, SEBASTIAN B. JøRGENSEN, MARTIN G. MYERS, RANDY J. SEELEY: "GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice", MOLECULAR METABOLISM, ELSEVIER, vol. 21, 1 March 2019 (2019-03-01), pages 13 - 21, XP055697810, ISSN: 2212-8778, DOI: 10.1016/j.molmet.2019.01.003 *

Also Published As

Publication number Publication date
JP2022523972A (ja) 2022-04-27
WO2020185533A1 (en) 2020-09-17
US20220152154A1 (en) 2022-05-19
EP3934679A1 (en) 2022-01-12
JP7536030B2 (ja) 2024-08-19
CA3131912A1 (en) 2020-09-17
MX2021010737A (es) 2021-09-28
JP2024156886A (ja) 2024-11-06
AU2020233876A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
US20220152154A1 (en) Growth differentiation factor 15 combination therapy
KR102927838B1 (ko) 이중 작용 단백질 및 이를 포함하는 약학적 조성물
US11858975B2 (en) Multi-domain active protein for treating metabolic diseases
JP7789871B2 (ja) グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
KR100879662B1 (ko) Ｇｌｐ-1 유사체 융합 단백질 제제
US20240327481A1 (en) Growth differentiation factor 15 fusion proteins
WO2020236762A2 (en) Variant single-chain insulin analogues
EP4495143A1 (en) Human insulin analogue, and fusion protein thereof and medical use thereof
WO2022143515A1 (zh) 一种人glp-1多肽变体及其应用
US20250346645A1 (en) Fusion protein and application thereof
CN113105561B (zh) 一种双靶点融合蛋白的制备方法和应用
CN109248323B (zh) 酰化的glp-1衍生物
KR20220157910A (ko) Gdf15 변이체 및 glp-1 수용체 작용제를 포함하는 병용 투여용 조성물
WO2022143516A1 (zh) 一种人glp-1多肽变体及其应用
WO2018188179A1 (zh) 胰高血糖素样肽-1受体激动剂融合蛋白及其应用
EA052546B1 (ru) Аналог человеческого инсулина, его слитый белок и их медицинское применение
WO2025178928A1 (en) Combination therapy for the treatment of obesity
CN118620086A (zh) 一种治疗糖尿病的融合蛋白及其应用
HK40091844A (en) Dual function proteins and pharmaceutical composition comprising same
HK1230958A1 (en) Composition for treating diabetes, containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)